Document is current
Any future updates will be listed below
-
Authors
Everts-Graber, Judith https://orcid.org/0000-0002-8792-8199
Ferrari, Serge
Popp, Albrecht
Hars, Magaly
Wenger, Mathias
Oser, Sven
Studer, Ueli
Steiner, Christian
Ziswiler, Hans-Rudolf
Schmid, Gernot
Reichenbach, Stephan
Lehmann, Thomas
Lamy, Olivier
Rodriguez, Elena Gonzalez
-
Funding
Funding for this research was provided by:
University of Bern
- License Information
-
More Information
Article History
Received: 9 April 2025
Accepted: 22 July 2025
First Online: 31 July 2025
Declarations
:
: SF: Amgen, UCB, Labatec, Gedeon Richter, Fresenius, Theramex, Agnovos. MW: UCB Pharma, Eli Lilly. SO: Amgen, Mylan. US: Janssen, Novartis, Pfizer, Sandoz, AbbVie, Amgen, Eli Lilly. CS: Abbvie. HRZ: Novartis, Jansen, Abbvie, Celgene. JEG, AP, GS, SR, TL, OL and EGR have nothing to declare. The authors declare no competing financial interests. The Swiss Osteoporosis Registry is sponsored by public and industrial support (). These sponsors had no role in the study design, the collection, analysis or interpretation of the data, the writing of the manuscript or the decision to submit the manuscript for publication. Publication of this article was not contingent upon approval by the study sponsors.
